Study Group: Physicians who Treat Schizophrenia (US)
Council Members in this Study Group: 371
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
- David Rosenberg, MD
Chief of Psychiatry and Psychology
CHILDREN'S HOSPITAL OF MICHIGAN
David Rosenberg, MD, is a tenured Professor and Miriam L Hamburger Endowed Chair of Psychiatry at Wayne State University and the Children's Hospital of Michigan. He is a board certified general and adult psychiatrist and pediatric psychiatrist. Dr. Rosenberg has authored first ever textbook on pediatric...
John Litton Jr., MDChief Executive Officer and President
Litton Family Medicine, PCJ. Scott Litton, Jr., MD, FAAFP, is the Chief Executive Officer and President of Litton Family Medicine, PC in Pennington Gap, VA. He provides inpatient services and also serves as the Medical Director of the Center for Wound Care at Lee Regional Medical Center. Dr. Litton serves as a Faculty member...
Amit Vijapura, MDOwner
AMIT VIJAPURA MDAmit Vijapura, MD, is a Private Practitioner in Psychiatry based in Florida. He has over 15 years of experience in the field and has expertise in depression, bipolar disorder, anxiety disorder, attention deficient disorder, and schizophrenia. Dr. Vijapura is board certified in Psychiatry and is also...
- Robert Schulte
Psychiatrist
North Scottsdale Psychiatric SpecialistsRobert Schulte, MD, is a Private Practitioner and a Psychiatrist at North Scottsdale Psychiatric Specialists in Arizona. He is board certified in Adult Psychiatry and Child and Adolescent Psychiatry with extensive experience with children and adult's re-psychotherapy and psychopharmacology and thetreatment...
- Rami Kaminski, MD
Founder and Director
Institute for Integrative PsychiatryRami Kaminski, MD, is Director and Founder of the Institute for Integrative Psychiatry in New York, a not-for-profit organization aimed at evaluating current psychiatric services and how they integrate with medicine, such as the mutual effects between medical and psychiatric conditions. Prior to that,...
- Lawrence Ginsberg, MD
President
RED OAK PSYCHIATRY ASSOCIATES, P. A.Lawrence Ginsberg, MD, is President and CEO of Red Oak Psychiatry Associates, PA, a multidisciplinary mental health group in Houston, Texas. Dr. Ginsberg's research interests include psychopharmacology, addiction medicine, and forensic psychiatry. His areas of clinical expertise are attention deficit...
GLG NewsSM Analyses by this Study Group's Leading Experts (?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Antidepressants Vary More in Side Effects, Not Efficacy
August 30, 2009
2nd Generation Antidepressants Prove Effective | health.usnews.com
[SIDE EFFECTS] The main differences among the newer antidepressants are side effects and drug interactions. See the Commentary for a drug-by-drug list of these key differences. [PCP's] This review comes from a group of primary care docs, which is important because most depression is treated by PCPs....
-
State Medicaid Cuts May Limit Market for New Antipsychotic Lurasidone
August 30, 2009
LURASIDONE DEMONSTRATED EFFICACY IN TREATING PATIENTS WITH SCHIZOPHRENIA IN PIVOTAL PHASE 3 STUDY | www.pipelinereview.com
Lurasidone is an atypical antipsychotic owned by Dainippon Sumitomo Pharma. Phase 3 PEARL 1 Study: 6-week, multi-site, double-blind placebo-controlled trial in 500 pts with DSM4 schizophrenia with PANSS score greater than 80. RESULTS: 80mg dose was superior to placebo; 40mg & 120mg was not....
-
Lurasidone will be an important new option for the treatment of Schizophrenia
August 29, 2009
LURASIDONE DEMONSTRATED EFFICACY IN TREATING PATIENTS WITH SCHIZOPHRENIA IN PIVOTAL PHASE 3 STUDY | www.pipelinereview.com
After much disappointment over the current Atypical Antipsychotics , Lurasidone shows great promise for treatment refractory Schizophrenics.
-
New Treatment Option for the Hearing Impaired
August 22, 2009
Oticon Medical Receives FDA Clearance To Market Innovative Bone Anchored Hearing System | www.medicalnewstoday.com
Oticon's new bone anchored hearing implant might offer unique advantages to the hearing impaired.
-
Treatment of Social Anxiety Disorderved
August 6, 2009
NeuroSearch successfully advances NSD-721 for treatment of social anxiety disorder and receives EUR 5 million in equity financing under the alliance with GlaxoSmithKline | www.pipelinereview.com
NeuroSearch new drug NSD-721 will be of great benefit to patients with Social Anxiety Disorder.
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Government/Military Hospital or Clinic
- Academic Institution*
- Consultancy, Healthcare-Focused
- Other Freestanding Healthcare Facility
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Owner
- Physician - Director
- Director
- President
- Medical Director
- Physician - Division Head
Related Study Groups
| Study Group Name | No. Members |
|---|---|
| Psychiatrists (US) | 1155 |
| Psychiatrists | 1554 |
| Physicians who Treat ADHD (US) | 459 |
| Physicians who Treat Depression (US) | 450 |
| Effexor XR Prescribers (US) | 148 |
| Seroquel Prescribers forSchizophrenia (US) | 109 |
| SSRI Prescribers (US) | 278 |